Kodiak Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Kodiak Sciences's earnings are forecast to decline at 14.5% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.5% pro Jahr.

Wichtige Informationen

-14.5%

Wachstumsrate der Gewinne

17.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	-299.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Feb 15

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Jan 24

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Oct 11

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Jul 19

Kodiak Sciences EPS in-line

May 10

Kodiak Sciences hits the capital raise button; shares dip after hours

Nov 16

Kodiak Sciences EPS misses by $0.12

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:KOD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-240	N/A	N/A	2
12/31/2024	N/A	-184	-55	-40	3
3/31/2024	N/A	-233	-176	-147	N/A
12/31/2023	N/A	-260	-196	-154	N/A
9/30/2023	N/A	-271	-197	-177	N/A
6/30/2023	N/A	-298	-224	-197	N/A
3/31/2023	N/A	-309	-252	-211	N/A
12/31/2022	N/A	-334	-254	-206	N/A
9/30/2022	N/A	-357	-263	-210	N/A
6/30/2022	N/A	-347	-286	-209	N/A
3/31/2022	N/A	-312	-266	-191	N/A
12/31/2021	N/A	-267	-246	-182	N/A
9/30/2021	N/A	-220	-208	-150	N/A
6/30/2021	N/A	-189	-150	-123	N/A
3/31/2021	N/A	-159	-114	-100	N/A
12/31/2020	N/A	-133	-90	-83	N/A
9/30/2020	N/A	-102	-70	-68	N/A
6/30/2020	N/A	-78	-51	-51	N/A
3/31/2020	N/A	-64	-50	-50	N/A
12/31/2019	N/A	-47	-40	-39	N/A
9/30/2019	N/A	-46	-37	-36	N/A
6/30/2019	N/A	-44	-34	-33	N/A
3/31/2019	N/A	-41	-26	-25	N/A
12/31/2018	N/A	-41	-30	-29	N/A
9/30/2018	N/A	-38	-26	-26	N/A
6/30/2018	N/A	-32	-26	-26	N/A
3/31/2018	N/A	-31	-25	-25	N/A
12/31/2017	N/A	-28	N/A	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KOD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KOD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KOD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von KOD schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: KOD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: KOD wird voraussichtlich in 3 Jahren unrentabel sein.

Kodiak Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 40% to US$2.63

No longer forecast to breakeven

Forecast to breakeven in 2025

Price target decreased to US$12.60

Price target decreased to US$117

Recent updates

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New major risk - Share price stability

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target decreased by 40% to US$2.63

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

No longer forecast to breakeven

Forecast to breakeven in 2025

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

New major risk - Share price stability

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

Insufficient new directors

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Insider notifies of intention to sell stock

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Price target decreased to US$12.60

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

Kodiak Sciences: Potential For Comeback After Trial Setback

Co-Founder recently sold US$12m worth of stock

Kodiak Sciences: KSI-301 Disappoints

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Insider notifies of intention to sell stock

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Insider notifies of intention to sell stock

Price target decreased to US$117

Insider notifies of intention to sell stock

Insider exercised options and sold US$376k worth of stock

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Senior VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider exercised options and sold US$705k worth of stock

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Kodiak Sciences EPS in-line

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences hits the capital raise button; shares dip after hours

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences EPS misses by $0.12

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell Microcap Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken